BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/13/2025 1:39:50 PM | Browse: 6 | Download: 14
 |
Received |
|
2025-03-27 02:28 |
|
Peer-Review Started |
|
2025-03-27 02:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-03 08:52 |
|
Revised |
|
2025-04-16 15:21 |
|
Second Decision |
|
2025-05-21 02:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-05-21 08:08 |
|
Articles in Press |
|
2025-05-21 08:08 |
|
Publication Fee Transferred |
|
2025-04-17 09:35 |
|
Edit the Manuscript by Language Editor |
|
2025-05-23 11:03 |
|
Typeset the Manuscript |
|
2025-06-04 05:17 |
|
Publish the Manuscript Online |
|
2025-06-13 13:39 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Ethics |
| Manuscript Type |
Case Report |
| Article Title |
Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiang-Lei Kong, Xi-Wei Lu, Si-Qi Dong, Jiao Liu, Lei Zheng, Lan-Lan Chen, Zi-Hui An, Li-Ming Gao and Jun-Li Cao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Science Research Project of Hebei Province in 2023, Key Laboratory of Research on Molecular Mechanism of Gastrointestinal Tumors in Qinhuangdao |
20231891 |
|
| Corresponding Author |
Jun-Li Cao, Department of Oncology, The First Hospital of Qinhuangdao, The Affiliated Qinhuangdao First Hospital of Hebei Medical University, No. 258 Wenhua Road, Qinhuangdao 066000, Hebei Province, China. kongxianglei@qhdsdyyy.com |
| Key Words |
Duodenal malignancy; Microsatellite instability-high; High expression of programmed cell death-ligand 1; Pembrolizumab; Complete clinical response; Case report |
| Core Tip |
Descending duodenal adenocarcinoma (DDA) is a rare malignancy of the digestive system. We treated a patient with DDA characterized by microsatellite instability-high (MSI-H) and high programmed cell death-ligand 1 expression, customizing the treatment regimen for individualized pembrolizumab therapy based on our clinical experience and disease assessment. The patient achieved long-term clinical remission with satisfactory results. This case underscores the advantages of individualized therapy and confirms that patients with mismatch-repair deficiency/MSI-H can derive significant benefits from pembrolizumab. |
| Publish Date |
2025-06-13 13:39 |
| Citation |
<p>Kong XL, Lu XW, Dong SQ, Liu J, Zheng L, Chen LL, An ZH, Gao LM, Cao JL. Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and review of literature. <i>World J Gastrointest Oncol</i> 2025; 17(6): 107568</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i6/107568.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i6.107568 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
